Objective: To review literature on the use of direct-acting oral anticoagulants (DOACs) in
patients with high body weight (BW) and/or high body mass index (BMI) and to make …

In 2016, the International Society on Thrombosis and Haemostasis (ISTH) published
guidelines advising caution when using direct oral anticoagulants (DOACs) in patients with …

Four direct‐acting oral anticoagulants (DOACs)–the thrombin inhibitor dabigatran, and the
activated factor X (FXa) inhibitors apixaban, edoxaban, and rivaroxaban–are approved in …

Obesity plays an essential role in the safety of pharmacologic drugs. There is paucity of data
for direct oral anticoagulants (DOACs) in the obese, despite these agents becoming more …

Abstract Background Direct oral anticoagulants (DOACs) are preferred over warfarin for the
treatment of venous thromboembolism (VTE) as well as atrial fibrillation (AF). The efficacy …

In clinical practice, direct oral anticoagulants (DOACs) are increasingly used for venous
thromboembolism treatment and prevention. A substantial proportion of patients with venous …

Although direct‐acting oral anticoagulants (DOACs) have widespread first‐line use for
treatment and prevention of venous thromboembolism (VTE), uncertainty remains regarding …

Phase III clinical trials for individual direct oral anticoagulants (DOACs) contained a limited
representation of subjects with abnormal body weight, which were mostly limited to a BMI> …

Despite evolving evidence, the use of direct oral anticoagulants (DOACs) in patients with
extremes of body weight remains controversial. This study aimed to measure the impact of …

Data on the impact of morbid obesity (body mass index [BMI]≥ 40 kg/m2) on the
pharmacokinetics (PK), pharmacodynamics (PD) of direct oral anticoagulants (DOACs) are …